Among the companies with shares expected to actively trade in Monday's session are Bristol-Myers Squibb Co. (BMY), Pfizer Inc. (PFE) and Momenta Pharmaceuticals Inc. (MNTA). Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) said the U.S. Food and Drug Administration has requested more information on their anti-clotting drug Eliquis. The request pushes back the potential for U.S. sales of the drug, which is already approved in Europe. Shares of the smaller Bristol-Myers dropped 4.6% to $33.75 in premarket trading while Pfizer shares were last trading down 2.3% to $22.21. Teva Pharmaceutical Industries Ltd. (TEVA) said a U.S. district court validated its patents for the multiple-sclerosis drug Copaxone and found purported generic versions by Mylan Inc. (MYL) and Momenta Pharmaceuticals Inc. (MNTA) infringe those patents. The news lifted Teva shares 7% to $40.70 premarket, while sending Momenta shares plunging 21% to $13.50 premarket. Shares of the larger Mylan were trading slightly lower at $21.10. Ventrus Biosciences Inc.'s (VTUS) hemorrhoidal disease treatment iferanserin failed to meet primary endpoints in a Phase 3 trial. Shares of the development-stage pharmaceutical plunged plunged 57% to $5.21 premarket as it said it has no immediate plans to continue the drug's development. Lexicon Pharmaceuticals Inc. (LXRX) said a study showed the combined use of its LX4211 with the established diabetes therapy metformin reduced the amount of glucose in patients with poorly controlled type 2 diabetes. Shares jumped 14% to $2.17 premarket. Watchlist: Moody's Investors Service raised its ratings on Dillard's Inc. (DDS) one notch closer to investment grade, citing the department-store operator's continued strong operating performance. Restaurant operator J. Alexander's Corp. (JAX) agreed to be acquired by a unit of insurer Fidelity National Financial Inc. (FNF) in a cash-and-stock deal that values it at roughly $72 million. Kirby Corp. (KEX) lowered its second-quarter and full-year earnings estimates, noting softness in its land-based diesel engine services business. Analysts at Goldman Sachs upgraded SanDisk Corp. (SNDK) to buy from neutral, saying current oversupply conditions should ease by the fourth quarter, helping the data-storage company to see better margins. St. Jude said late Friday that it has identified a single Durata defibrillator lead that was damaged due to an external abrasion, but said the lead did not have the critical flaw of an earlier version of the device that St. Jude no longer sells. -Write to Mia Lamar at mia.lamar@dowjones.com
